We are one of the 8 French medtech companies who have been selected to participate in the Soft Landing Boston 2018 program. Soft Landing Boston is a program dedicated to medtech and e-health companies (focused on medical devices, connected objects, and tools for diagnosis and monitoring). Designed by French Tech Hub, Medicen Paris region, BPIfrance and Mednest, this program aims to support companies in the development of their innovative solutions for the North American market.
This one-week program (23-27 April 2018) will allow us to better understand how the US market is organized from a regulatory, reimbursement, and market access standpoint. It will also be an opportunity to meet many experts who can guide us in adjusting our product for the most important diabetes market.